

Lucentis[®] (ranibizumab) Byooviz[™] (ranibizumab-nuna)

Cimerli[®] (ranibizumab-eqrn) Injectable Medication Request

1-888-267-3277 For Medicare Advantage Part B: Please Use Medicare Request Form

FAX:

Aetna Precertification Notification Phone: <u>1-866-752-7021</u> (TTY: <u>711</u>)

Page 1 of		N. C.					
·	nust be completed and legi	<u> </u>	•				
Please indicate: Start of treatment, start date:		☐ Continuation o	f therapy, date of la				
Precertification Requested By:		Phoi	ne:	Fax	C:		
A. PATIENT INFORMATION							
First Name:	Last Name:			DOB:			
Address:	-	City:		State:	ZIP:		
Home Phone: Work Phone	ı:	Cell Phone:		E-mail:	1		
Current Weight: lbs or kgsHeight:	inches orcms	Allergies:					
B. INSURANCE INFORMATION							
Member ID #:	Does patient have o	other coverage?	☐ Yes ☐ No				
Group #:			Carrier Name:				
Insured:	Insured:						
Medicare: ☐ Yes ☐ No If yes, provide ID #:			☐ No If yes, provide	: ID #:			
C. PRESCRIBER INFORMATION							
First Name:	Last Name:		(Check one)	: M.D.	D.O. N.P. P.A.		
Address:	1	City:		State:	ZIP:		
Phone: Fax:	St Lic #:	NPI#:	DEA #:		UPIN:		
Provider E-mail:	Office Contact Nam			Phone:			
Specialty (Check one):	Other [.]						
D. DISPENSING PROVIDER/ADMINISTRATION INF					_		
Place of Administration:	ORWATION	Diananaina	n Drovidor/Dhormo	ou (Potiont o	polostad abaica)		
		Dispensing Provider/Pharmacy: (Patient selected choice)					
Self-administered Physician's Offic		=		Retail Pharma	•		
			ty Pharmacy 🔲 🤇	Other:			
Center Name: Home Infusion Center Phone:		— Name:	- Name:				
l a si		Address.					
Agency Name:			Phone: FAX:				
Address:		TIN:		PIN	l:		
E. PRODUCT INFORMATION							
Request is for: Lucentis (ranibizumab)	Byooviz (ranibizumab-nı	una) 🗌 Cimerli ((ranibizumab-egrn)			
Dose:	-			, 			
F. DIAGNOSIS INFORMATION - Please indicate prin	mary ICD code and specify	any other any other	r where applicable (*).			
	Oth						
G. CLINICAL INFORMATION - Required clinical info	rmation must be completed	d for ALL precertifica	ation requests.				
For All Requests (clinical documentation requi		'					
Please select the diagnosis:							
Diabetic macular edema							
☐ Diabetic retinopathy							
☐ Macular edema following retinal vein occlusion							
☐ Myopic choroidal neovascularization							
☐ Neovascular (wet) age- related macular degen	eration						
For Lucentis Requests Only:							
☐ Yes ☐ No Has the patient had an ineffective	response, contraindication	on or intolerance to	o Avastin?				
	☐ Yes ☐ No Has the patient had an ineffective response, contraindication or intolerance to Byooviz OR Cimerli?						
For Byooviz and Cimerli Requests Only:			•				
Yes No Has the patient had an ineffective	response, contraindication	on or intolerance to	o Avastin?				
For Continuation Requests (clinical documenta	•						
Yes No Has the patient demonstrated a p			provement or maint	enance in he	st corrected visual acuity		
[BCVA] or visual field, or a reducti							



Lucentis[®] (ranibizumab) Byooviz[™] (ranibizumab-nuna) Cimerli[®] (ranibizumab-eqrn) Injectable Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification Phone: <u>1-866-752-7021</u> (TTY: <u>711</u>)

FAX: <u>1-888-267-3277</u>

For Medicare Advantage Part B: Please Use Medicare Request Form

Patient First Name	Patient Last Name Patient Phone		Patient DOB					
			<u> </u>					
H. ACKNOWLEDGEMENT								
Request Completed By (Signature Required):			Date:/	1				
Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.								

The plan may request additional information or clarification, if needed, to evaluate requests.